Senores Pharmaceuticals Ltd
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]
- Market Cap ₹ 2,628 Cr.
- Current Price ₹ 571
- High / Low ₹ 665 / 435
- Stock P/E 83.5
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 11.5 %
- ROE 25.2 %
- Face Value ₹ 10.0
Pros
Cons
- Company might be capitalizing the interest cost
- Company has high debtors of 191 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Part of BSE Healthcare BSE IPO BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 14 | 35 | 215 | |
| 12 | 23 | 173 | |
| Operating Profit | 2 | 13 | 42 |
| OPM % | 14% | 36% | 19% |
| 0 | 4 | 3 | |
| Interest | 1 | 2 | 9 |
| Depreciation | 1 | 2 | 10 |
| Profit before tax | 1 | 12 | 25 |
| Tax % | 13% | 32% | -31% |
| 1 | 8 | 33 | |
| EPS in Rs | 1.01 | 8.59 | 10.31 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 507% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 273% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 25% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 9 | 10 | 31 |
| Reserves | 28 | 36 | 174 |
| 15 | 63 | 258 | |
| 8 | 23 | 160 | |
| Total Liabilities | 59 | 131 | 622 |
| 7 | 27 | 235 | |
| CWIP | 8 | 34 | 97 |
| Investments | 15 | 16 | 0 |
| 29 | 53 | 289 | |
| Total Assets | 59 | 131 | 622 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| -10 | -1 | -20 | |
| -24 | -48 | -54 | |
| 36 | 46 | 87 | |
| Net Cash Flow | 2 | -3 | 13 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 506 | 228 | 191 |
| Inventory Days | 135 | 89 | 129 |
| Days Payable | 324 | 388 | 389 |
| Cash Conversion Cycle | 317 | -71 | -70 |
| Working Capital Days | 414 | 316 | 181 |
| ROCE % | 18% | 12% |
Documents
Announcements
-
Closure of Trading Window
1d - Trading window closure from April 01, 2025.
-
Intimation Under Regulation 30(6) Of SEBI (LODR) Regulations, 2015.
20 Mar - Investment of USD 468,640 in Senores Pharmaceuticals Inc.
-
Additional Disclosure In Respect Of Our Intimation Dated March 11, 2025, Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015 ('Listing Regulations')
12 Mar - Acquisition increases shareholding in Havix to 54.96%.
-
Announcement under Regulation 30 (LODR)-Acquisition
11 Mar - Acquisition of 3.73% equity shares in Havix Group.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
4 Mar - Senores Pharmaceuticals acquires 14 ANDAs from Dr. Reddy's Laboratories.
Concalls
-
Jan 2025Transcript PPT REC
Business Overview:[1]
SPL is global research driven pharmaceutical company which develops and manufactures
pharmaceutical products for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Company develops and manufactures specialty, underpenetrated and complex pharmaceutical products. It also manufactures criticalcare injectables and APIs